SCHEMBL1309976

SCHEMBL1309976

CC(=O)OC1CN(c2ccc(C)cc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
AKR1C3 P42330 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
ACACB O00763 3/20 0.40
LMNA P02545 3/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
ADRB1 P08588 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CCR1 P32246 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27919927 0.85 GFER (0.50) MAPTALDH1A1ACACBKDM4EMEN1
SCHEMBL27938419 0.80 MAPT (0.52) MAPTALDH1A1LMNAADRB1SMN1; SMN2
SCHEMBL17326795 0.77 AKR1C3 (0.44) MAPTALDH1A1AKR1C3GPR119LMNA
SCHEMBL21256812 0.76 ADRB1 (0.44) MAPTALDH1A1AKR1C3GPR119LMNA
SCHEMBL13920426 0.75 HTR2A (0.40) ACACBKMT2A
SCHEMBL1309978 0.73 AR (0.44) MAPTALDH1A1AKR1C3ADRB1KMT2A
SCHEMBL17326843 0.72 NAMPT (0.49) MAPTALDH1A1AKR1C3GPR119LMNA
SCHEMBL17392415 0.72 NOTUM (0.55) MAPTGPR119ACACBMEN1KMT2A
SCHEMBL17392419 0.72 NOTUM (0.55) MAPTGPR119ACACBMEN1KMT2A
SCHEMBL21261031 0.71 ADRB1 (0.40) MAPTALDH1A1ACACBLMNAADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110274638-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274638-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS CYP2D6, CYP51A1, CYP2C19 MAPT 4351/4885ALDH1A1 319/4885AKR1C3 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.